High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT)

被引:53
作者
Burdach, S [1 ]
Jürgens, H
机构
[1] Univ Halle Wittenberg, Div Pediat Hematol Oncol, D-06097 Halle An Der Saale, Germany
[2] Univ Halle Wittenberg, Childrens Canc Res Ctr, D-06097 Halle An Der Saale, Germany
[3] Univ Munster, Dept Pediat Hematol Oncol, D-48129 Munster, Germany
关键词
Ewing family of tumors; high-dose chemotherapy; risk adapted treatment; stratification criteria; stem cell transplantation; immunotherapy; TBI;
D O I
10.1016/S1040-8428(01)00154-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
EFT is defined by the expression of ews/ets fusion genes. The type of the fusion transcript impacts on the clinical biology. EFT requires risk adapted treatment. A risk-adapted treatment is determined by tumor localisation, tumor stage and volume. For metastatic and relapsed disease the pattern of spread and the time of relapse are the determinants of risk stratification. Staging of Ewing tumors has been considerably improved by magnetic resonance imaging and modern isotope scanning techniques. However, the determination of the extent of the metastatic spread in particular number of involved bones remains an unresolved issue. The prognosis for high-risk Ewing tumors has been improved by rnultimodal and high-dose radio/chemotherapy (HDC). The concepts for high-dose therapy in Ewing tumors are based on dose response and dose intensity relationships. In single agent HDC most experience exists with Melphalan. Several chemotherapeutic agents have been used in combination HDC with or without TBI such as Adriamycin, BCNU, Busulphan, Carboplatin, Cyclophosphamide, Etoposide, Melphalan. Thiotepa Procarbazin and Vincristine. Todate, superiority of any high-dose chemotherapy regimen has not been established. However, the clinical biology, the pattern of spread and the time of relapse determine the prognosis of patient who are eligible for HDC. In particular, patients with multifocal bone or bone marrow metastases have a poorer prognosis than patients with lung metastases. In addition, patients with a relapse within 24 months have a poorer prognosis than patients with a relapse later than 24 months after diagnosis. This review will analyze the results of single- and multi-agent chemotherapy with respect to agent combination, dose and risk stratum of patient population. Future therapeutic modalities for the treatment of EFT might encompass immunotherapeutic and genetic strategies including allogencic stem cell transplantation. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:169 / 189
页数:21
相关论文
共 178 条
[1]  
ABRAMS RA, 1980, LANCET, V2, P385
[2]  
Ahrens S, 1999, MED PEDIATR ONCOL, V32, P186, DOI 10.1002/(SICI)1096-911X(199903)32:3<186::AID-MPO5>3.0.CO
[3]  
2-D
[4]  
ALLAM K, 1994, AM J NEURORADIOL, V15, P305
[5]   Relation of neuroglial marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family [J].
Amann, G ;
Zoubek, A ;
Salzer-Kuntschik, M ;
Windhager, R ;
Kovar, H .
HUMAN PATHOLOGY, 1999, 30 (09) :1058-1064
[6]  
AMANN G, 1996, MED PEDIATR ONCOL, V27, P256
[7]   Autologous stem cell transplantation in solid tumours of childhood [J].
Atra, A ;
Pinkerton, CR .
ANNALS OF MEDICINE, 1996, 28 (02) :159-164
[8]   High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma [J].
Atra, A ;
Whelan, JS ;
Calvagna, V ;
Shankar, AG ;
Ashley, S ;
Shepherd, V ;
Souhami, RL ;
Pinkerton, CR .
BONE MARROW TRANSPLANTATION, 1997, 20 (10) :843-846
[9]   EWING SARCOMA - EXVIVO SENSITIVITY TOWARDS NATURAL AND LYMPHOKINE-ACTIVATED KILLING [J].
ATZPODIEN, J ;
GULATI, SC ;
SHIMAZAKI, C ;
BUHRER, C ;
OZ, S ;
KWON, JH ;
KOLITZ, JE ;
CLARKSON, BD .
ONCOLOGY, 1988, 45 (06) :437-443
[10]  
Bacci G, 1999, ONCOL REP, V6, P807